These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 371802)

  • 1. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
    Friedman MA; Kaufman DA; Williams JE; Resser KJ; Rosenbaum EH; Cohen RJ; Glassberg AB; Blume MR; Gershow J; Chan EY
    Cancer Treat Rep; 1979 Mar; 63(3):493-5. PubMed ID: 371802
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 7. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of metastatic malignant melanoma (author's transl)].
    Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
    Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
    Gundersen S
    Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
    [No Abstract]   [Full Text] [Related]  

  • 16. cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.
    Karakousis CP; Getaz EP; Bjornsson S; Henderson ES; Irequi M; Martinez L; Ospina J; Cavins J; Preisler H; Holyoke E; Holtermann O
    Cancer Treat Rep; 1979; 63(11-12):2009-10. PubMed ID: 393386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
    Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
    Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of malignant melanoma using DTIC].
    Zaumseil RP; Fiedler H; Lübbe D
    Dermatol Monatsschr; 1977 Nov; 163(11):905-14. PubMed ID: 590586
    [No Abstract]   [Full Text] [Related]  

  • 19. Dacarbazine (DTIC) in malignant melanoma.
    Drug Ther Bull; 1976 May; 14(10):39-40. PubMed ID: 976088
    [No Abstract]   [Full Text] [Related]  

  • 20. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.